Document Detail


Management of acute non-Q-wave myocardial infarction. The role of prophylactic diltiazem therapy and indications for predischarge coronary arteriography.
MedLine Citation:
PMID:  1718699     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Non-Q-wave myocardial infarction (MI) differs from Q-wave MI in 3 important respects: a smaller infarct size, possibly due to early reperfusion resulting from spontaneous thrombolysis, relief of spasm, or both; more frequency patency of the infarct-related artery; and a larger residual mass of viable but jeopardized myocardium within the perfusion zone of the infarct-related vessel. Left ventricular function is generally better unless impaired by previous MI. After the acute phase, the prognosis is worse when residual ischaemia is present, and reinfarction rates during hospitalisation and in the subsequent year of follow-up are higher. As myocardial ischaemia is potentially reversible, its presence should be actively sought in all patients with recognised non-Q-wave MI. On the basis of current knowledge and available data, the following guidelines for the management of non-Q-wave MI patients can be recommended: (1) diltiazem and aspirin should be administered to all patients as soon as the diagnosis is established, unless contraindications exist; (2) patients who develop early recurrent ischaemia on therapy (i.e. angina with associated ST-T-wave changes) should undergo prompt cardiac catheterisation and myocardial revascularisation; and (3) patients with entirely uncomplicated hospital histories who are asymptomatic should undergo exercise stress testing, preferably in conjunction with 201Tl perfusion scintigraphy, before hospital discharge. Only those patients with evidence of significant residual ischaemia need cardiac catheterisation and myocardial revascularisation.
Authors:
R S Gibson
Related Documents :
6846119 - Myocardial infarct extension: prevalence, clinical significance, and problems in diagno...
11392189 - Directional coronary atherectomy in acute myocardial infarction.
19442939 - Adipose tissue detected by multislice computed tomography in patients after myocardial ...
19559709 - Extracellular matrix turnover and signaling during cardiac remodeling following mi: cau...
3168199 - Autonomic mechanisms and sudden death. new insights from analysis of baroreceptor refle...
12271109 - Diurnal variations in coagulation and fibrinolysis in vital exhaustion.
16209989 - Preprocedural thrombolysis in myocardial infarction (timi) flow significantly affects t...
21262079 - A comparison of cardiac post-conditioning and remote pre-conditioning in paediatric car...
16036019 - Pharmacologic effects on cardiac remodeling.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Review    
Journal Detail:
Title:  Drugs     Volume:  42 Suppl 2     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  1991  
Date Detail:
Created Date:  1991-12-17     Completed Date:  1991-12-17     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  28-37     Citation Subset:  IM    
Affiliation:
Division of Cardiology, University of Virginia Health Sciences Center, Charlottesville.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use
Aspirin / therapeutic use*
Calcium Channel Blockers / therapeutic use
Coronary Angiography
Diltiazem / therapeutic use*
Electrocardiography
Humans
Myocardial Infarction / drug therapy*,  physiopathology
Recurrence
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Calcium Channel Blockers; 42399-41-7/Diltiazem; 50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Basic mechanisms involved in the protection of the ischaemic myocardium. The role of calcium antagon...
Next Document:  Myocardial infarction. Secondary prevention with nifedipine.